

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SciClone Pharmaceuticals (Holdings) Limited

賽生藥業控股有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6600)

POSITIVE PROFIT ALERT

This announcement is made by SciClone Pharmaceuticals (Holdings) Limited (the “**Company**” or “**SciClone Pharmaceuticals**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 (2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (“**Directors**”) of the Company is pleased to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the information currently available to the Company and a preliminary assessment of the Group’s unaudited consolidated management accounts for the year ended December 31, 2021 (“**FY2021**”), the Group is expected to record an unaudited profit attributable to shareholders of the Company of not less than RMB915 million for FY2021, as compared to the profit attributable to shareholders of approximately RMB754 million for the year ended December 31, 2020 (“**FY2020**”). Such increase was primarily attributable to the continuous growth of revenue from brisk sales of our proprietary product Zadaxin and commercial launch of in-licensed products. The impact of the profit above is partially counteracted by the following factors: (i) the increase in research and development costs for Zadaxin clinical studies and pipeline candidates in FY2021; and (ii) the rise in selling and marketing expenses due to the expansion of our sales and marketing team and also the low base in FY2020 when market development and business promotion activities were interrupted by the outbreak of COVID-19.

The information contained in this announcement only represents a preliminary assessment of the Group’s unaudited consolidated management accounts for FY2021 and other information made available to the Board as at the date hereof and such information has not been reviewed or audited by the independent auditor of the Company or reviewed by the Audit Committee of the Company. The actual results of the Group for FY2021 may be subject to change and may differ from the information contained in this announcement as the Company is still in the process of finalizing the annual results for FY2021, which will be announced before the end of March 2022 in accordance with the requirements of the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
SciClone Pharmaceuticals (Holdings) Limited
ZHAO Hong
Executive Director, Chief Executive Officer and President

Hong Kong, February 25, 2022

As at the date of this announcement, the Board comprises Mr. Zhao Hong as executive director, Mr. Li Zhenfu, Dr. Daniel Luzius Vasella, Ms. Lin Shirley Yi-Hsien, Ms. Li Quan, Mr. Shi Cen and Ms. Wang Haixia as non-executive directors, and Dr. Liu Guoen, Dr. Chen Ping, Mr. Gu Alex Yushao and Ms. Wendy Hayes as independent non-executive directors.

** for identification purpose only*